Literature DB >> 9308957

Conformal episcleral plaque therapy.

M A Astrahan1, G Luxton, Q Pu, Z Petrovich.   

Abstract

PURPOSE: Episcleral plaque therapy (EPT) with sealed 125I sources is widely used in the treatment of choroidal melanoma. In EPT, as elsewhere in radiotherapy, concern for normal tissue tolerance has frequently been a dose-limiting factor. The concept of conformal therapy, which seeks to improve dose homogeneity within the tumor and greatly reduce the dose to uninvolved structures may provide a solution to this problem. Radioactive sources are typically distributed uniformly over the surface of an episcleral plaque and are sometimes offset slightly from the scleral surface to reduce the dose to the sclera relative to the apex and prescribed therapeutic margin at the tumor base. Nevertheless, it is not uncommon for scleral dose to exceed the dose to the apex of intermediate to tall tumors by a factor of 4 or more. The availability of low-energy sealed sources such as 125I prompted the development of gold-backed plaques to shield noninvolved periocular tissues. The concept of shielding can be extended to include collimation of individual sources. The potential advantages of individual source collimation include reduced scleral dose, more homogeneous tumor dose, and superior shielding of adjacent normal structures such as the fovea as compared to previous plaque designs. METHODS AND MATERIALS: A three-dimensional treatment-planning system has been extended to design a plaque that incorporates individually collimated 125I sources. Thermoluminescent dosimetry (TLD) and radiochromic film were used to compare calculated dose-rate distributions with measured dose rates in an acrylic phantom.
RESULTS: Calculations predict that source collimation in the form of a "slotted" gold plaque will achieve the purposes of the study. The collimating effect of the slots is demonstrated qualitatively using radiochromic film, and the accuracy of the calculation is demonstrated quantitatively with TLD.
CONCLUSION: The episcleral plaque described in this report is simpler to assemble than previous plaque designs. It produces a more homogeneous dose distribution in the tumor, reduces scleral dose by up to 50% as compared to conventional designs, and significantly reduces radiation dose to uninvolved structures adjacent to the plaque.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308957     DOI: 10.1016/s0360-3016(97)00118-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Finger's "slotted" eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours.

Authors:  Paul T Finger
Journal:  Br J Ophthalmol       Date:  2007-02-27       Impact factor: 4.638

2.  Quantifying Subclinical and Longitudinal Microvascular Changes Following Episcleral Plaque Brachytherapy Using Spectral Domain-Optical Coherence Tomography Angiography.

Authors:  Kyle M Green; Brian C Toy; Bright S Ashimatey; Debarshi Mustafi; Richard L Jennelle; Melvin A Astrahan; Zhongdi Chu; Ruikang K Wang; Jonathan Kim; Jesse L Berry; Amir H Kashani
Journal:  J Vitreoretin Dis       Date:  2020-08-13

3.  Novel low-kVp beamlet system for choroidal melanoma.

Authors:  Carlos Esquivel; Clifton D Fuller; Robert G Waggener; Adrian Wong; Martin Meltz; Melissa Blough; Tony Y Eng; Charles R Thomas
Journal:  Radiat Oncol       Date:  2006-09-11       Impact factor: 3.481

4.  The retina dose-area histogram: a metric for quantitatively comparing rival eye plaque treatment options.

Authors:  Melvin A Astrahan
Journal:  J Contemp Brachytherapy       Date:  2013-03-29

5.  Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity.

Authors:  Nolan L Gagne; Daniel R Cutright; Mark J Rivard
Journal:  J Contemp Brachytherapy       Date:  2012-09-29

6.  Comparison of 16 mm OSU-Nag and COMS eye plaques.

Authors:  Hualin Zhang; Frederick Davidorf; Yujin Qi
Journal:  J Appl Clin Med Phys       Date:  2012-05-10       Impact factor: 2.102

Review 7.  Recent advancements in the management of retinoblastoma and uveal melanoma.

Authors:  Amy C Schefler; Ryan S Kim
Journal:  F1000Res       Date:  2018-04-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.